Ike Ogbaa

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

Julio Rosenstock, William T. Cefalu, Pablo Lapuerta et al. · Diabetes Care · 2014 · 78 citations · Full text

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa et al. · Clinical Therapeutics · 2013 · 77 citations

Metabolic Syndrome, Diabetes Management, Diabetes +8

Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier et al. · Clinical Therapeutics · 2013 · 65 citations

Metabolic Syndrome, Molecular Pharmacology, Healthy Subjects +10

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results

Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos et al. · Nephrology Dialysis Transplantation · 2021 · 60 citations · Full text

LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion

Brian Zambrowicz, Pablo Lapuerta, Paul Strumph et al. · Clinical Therapeutics · 2014 · 49 citations

Metabolic Syndrome, Diabetes Management, Urology +8